Andreas Argyrides
Stock Analyst at Oppenheimer
(4.52)
# 324
Out of 4,650 analysts
96
Total ratings
53.66%
Success rate
22.81%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andreas Argyrides
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BNTC Benitec Biopharma | Initiates: Outperform | $35 | $10.83 | +223.18% | 1 | Oct 16, 2024 | |
| LRMR Larimar Therapeutics | Initiates: Outperform | $26 | $7.78 | +234.19% | 1 | Oct 16, 2024 | |
| RGLS Regulus Therapeutics | Reiterates: Outperform | $7 | $1.61 | +334.78% | 1 | Aug 14, 2024 | |
| RANI Rani Therapeutics Holdings | Initiates: Outperform | $17 | $2.34 | +626.50% | 4 | Aug 2, 2024 | |
| LQDA Liquidia | Initiates: Perform | n/a | $11.04 | - | 6 | Jun 25, 2024 | |
| MLTX MoonLake Immunotherapeutics | Initiates: Outperform | $104 | $48.19 | +115.81% | 14 | Jun 25, 2024 | |
| KROS Keros Therapeutics | Initiates: Outperform | $102 | $60.14 | +69.60% | 5 | Jun 25, 2024 | |
| CLSD Clearside Biomedical | Initiates: Outperform | $5 | $1.05 | +376.19% | 1 | Jun 25, 2024 | |
| GOSS Gossamer Bio | Initiates: Outperform | $9 | $0.91 | +884.36% | 8 | Jun 25, 2024 | |
| SPRY ARS Pharmaceuticals | Reiterates: Outperform | $19 | $15.17 | +25.25% | 9 | Mar 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $9 | $5.66 | +59.01% | 4 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $29 | $16.97 | +70.89% | 3 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $21 | $9.06 | +131.79% | 4 | Feb 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $224 | $130.21 | +72.03% | 4 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $57 | $17.18 | +231.78% | 2 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $207 → $225 | $126.77 | +77.49% | 8 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $1.40 | - | 6 | Nov 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $5 → $7 | $1.31 | +434.35% | 3 | Oct 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $10 | $6.87 | +45.56% | 1 | Oct 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $10 | $2.00 | +400.00% | 5 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $73 → $70 | $69.91 | +0.13% | 6 | Aug 1, 2023 |
Benitec Biopharma
Oct 16, 2024
Initiates: Outperform
Price Target: $35
Current: $10.83
Upside: +223.18%
Larimar Therapeutics
Oct 16, 2024
Initiates: Outperform
Price Target: $26
Current: $7.78
Upside: +234.19%
Regulus Therapeutics
Aug 14, 2024
Reiterates: Outperform
Price Target: $7
Current: $1.61
Upside: +334.78%
Rani Therapeutics Holdings
Aug 2, 2024
Initiates: Outperform
Price Target: $17
Current: $2.34
Upside: +626.50%
Liquidia
Jun 25, 2024
Initiates: Perform
Price Target: n/a
Current: $11.04
Upside: -
MoonLake Immunotherapeutics
Jun 25, 2024
Initiates: Outperform
Price Target: $104
Current: $48.19
Upside: +115.81%
Keros Therapeutics
Jun 25, 2024
Initiates: Outperform
Price Target: $102
Current: $60.14
Upside: +69.60%
Clearside Biomedical
Jun 25, 2024
Initiates: Outperform
Price Target: $5
Current: $1.05
Upside: +376.19%
Gossamer Bio
Jun 25, 2024
Initiates: Outperform
Price Target: $9
Current: $0.91
Upside: +884.36%
ARS Pharmaceuticals
Mar 11, 2024
Reiterates: Outperform
Price Target: $19
Current: $15.17
Upside: +25.25%
Mar 7, 2024
Maintains: Outperform
Price Target: $4 → $9
Current: $5.66
Upside: +59.01%
Mar 6, 2024
Reiterates: Outperform
Price Target: $29
Current: $16.97
Upside: +70.89%
Feb 28, 2024
Reiterates: Neutral
Price Target: $21
Current: $9.06
Upside: +131.79%
Feb 20, 2024
Reiterates: Outperform
Price Target: $224
Current: $130.21
Upside: +72.03%
Feb 8, 2024
Reiterates: Outperform
Price Target: $57
Current: $17.18
Upside: +231.78%
Feb 8, 2024
Maintains: Outperform
Price Target: $207 → $225
Current: $126.77
Upside: +77.49%
Nov 16, 2023
Upgrades: Outperform
Price Target: n/a
Current: $1.40
Upside: -
Oct 10, 2023
Maintains: Outperform
Price Target: $5 → $7
Current: $1.31
Upside: +434.35%
Oct 10, 2023
Initiates: Outperform
Price Target: $10
Current: $6.87
Upside: +45.56%
Aug 11, 2023
Maintains: Outperform
Price Target: $16 → $10
Current: $2.00
Upside: +400.00%
Aug 1, 2023
Maintains: Neutral
Price Target: $73 → $70
Current: $69.91
Upside: +0.13%